Immunology Market Gains Momentum with Advanced Drug Approvals | CAGR of 6.3% from 2024 to 2033

PORTLAND, HI, UNITED STATES, November 6, 2025 /EINPresswire.com/ -- According to the report, the immunology market was valued at $110.1 billion in 2023, and is estimated to reach $204.0 billion by 2033, growing at a CAGR of 6.3% from 2024 to 2033.

Prime determinants of growth

Increase in prevalence of chronic diseases, rise in awareness and understanding of immune-related diseases, and increase in investment in research and development are the major factors that drive the growth of the immunology market. However, stringent regulatory requirements restricts the market growth. Moreover, advancements in biotechnology and molecular biology offers remunerative opportunities for the expansion of the global immunology market.

Request Sample of the Report on Immunology Market Forecast 2033 – https://www.alliedmarketresearch.com/request-sample/A298165

Recent Developments

In March 2024, Gilead Sciences, Inc. and Xilio Therapeutics, Inc. announced an exclusive license agreement to develop and commercialize Xilio's Phase 1 tumor-activated IL-12 program, XTX301. Xilio Therapeutics is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies.

In May 2023, Gilead Sciences, Inc. and Arcus Biosciences, Inc. announced that the companies have expanded the previously announced research collaboration focused on oncology to include therapies for the treatment of inflammatory diseases. The expanded collaboration builds upon Gilead's growing presence in inflammatory disease and serves as a step towards broadening Arcus' capabilities and portfolio beyond oncology and into inflammation.

Want to Explore More, Connect to our Analyst – https://www.alliedmarketresearch.com/connect-to-analyst/A298165

Immunology Market Segment Highlights

The biopharmaceuticals segment to maintain its leadership status during the forecast period

By product type, biopharmaceuticals segment dominated the market share in 2023. This is attributed to biopharmaceuticals offer targeted and precise mechanisms of action, resulting in enhanced efficacy and safety profiles compared to conventional drugs. The ongoing therapeutic innovations, expanding indications, rise in investment in R&D, coupled with advancements in biotechnology and personalized medicine approaches propel the segment growth.

The autoimmune disease segment to maintain its leadership status during the forecast period

By application, autoimmune disease segment dominated the market share in 2023. The increase in prevalence of autoimmune disorders worldwide is driving significant attention and investment towards research, diagnosis, and treatment options. With growing awareness and improved diagnostic techniques, more cases are being identified, leading to a greater demand for effective therapies.

The hospitals and clinics segment to maintain its leadership status during the forecast period

By end user, hospitals and clinics segment dominated the market share in 2023. Hospitals and clinics serve as primary points of care for patients with immunological disorders, providing comprehensive diagnostic, therapeutic, and follow-up services. In addition, the rise in prevalence of autoimmune and inflammatory conditions necessitates increased patient access to specialized healthcare facilities for timely diagnosis and treatment thereby driving the segment growth. Furthermore, these healthcare settings serve as hubs for clinical research and trials, driving innovation and advancements in immunology treatments which further support the segment growth.

For Purchase Related Queries/Inquiry – https://www.alliedmarketresearch.com/purchase-enquiry/A298165

Regional Outlook

North America to maintain its dominance by 2033

In North America and Europe there is a robust market for immunology due to advanced healthcare systems, rise in prevalence of chronic pain conditions, and greater accessibility to healthcare services. These regions also witness significant research and development activities, leading to the introduction of innovative pain management therapies and medications. In emerging markets such as Asia-Pacific and LAMEA the immunology market is experiencing rapid growth driven by increasing healthcare expenditure, expanding pharmaceutical industries, and rising awareness about pain management.

Key Players:

AbbVie Inc.
Johnson & Johnson
Pfizer Inc.
Novartis AG
Merck & Co., Inc.
Bristol-Myers Squibb Company
Amgen Inc
Eli Lilly and Company
Gilead Sciences, Inc.
Sanofi

Read More:

Orphan Drugs Market Set to Surge Amid Rare Disease Awareness | Registering a CAGR of 11.8% from 2021 to 2030

About Us

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

David Correa
Allied Market Research
+ + + + + +1 800-792-5285
email us here
Visit us on social media:
LinkedIn
Facebook
YouTube
X
